News articles about Akorn (NASDAQ:AKRX) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Akorn earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.6922411492349 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Basic Trading and Ownership Data for Akorn, Inc. (AKRX) – Market Movers (financialqz.com)
- Notable Tuesday Option Activity: AKRX, ROK, CBRL (nasdaq.com)
- Akorn, Inc. (AKRX) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- Fresenius CFO backs acquisition course: Boersen-Zeitung (reuters.com)
Shares of Akorn (NASDAQ AKRX) traded down $0.01 during trading hours on Friday, reaching $33.55. 1,240,074 shares of the company traded hands, compared to its average volume of 1,400,000. The firm has a market capitalization of $4,200.00, a PE ratio of 56.86, a price-to-earnings-growth ratio of 1.73 and a beta of 1.33. Akorn has a 52-week low of $17.74 and a 52-week high of $34.00. The company has a current ratio of 4.16, a quick ratio of 3.17 and a debt-to-equity ratio of 0.92.
In related news, Director Brian Tambi sold 15,100 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $33.35, for a total value of $503,585.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 28.20% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This article was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2018/01/13/akorn-akrx-receives-daily-media-sentiment-rating-of-0-17.html.
Akorn Company Profile
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
What are top analysts saying about Akorn? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Akorn and related companies.